synopsis mule

14
1 Seminar On Seminar On Synopsis For M.Pharm Dissertation By MULE MADHAV SHESHERAO Under the Guidance of Guide Mr. Kshirsagar R. V. Asst. Professor School of pharmacy SRTMU Nanded Industrial Guide Mr. N. K. Shinde Senior Executive Lupin Research Park School of Pharmacy, SRTMU, Nanded.

Upload: madhavmule

Post on 26-May-2015

952 views

Category:

Education


3 download

DESCRIPTION

protocol

TRANSCRIPT

Page 1: Synopsis mule

1

Seminar OnSeminar On

Synopsis For M.Pharm Dissertation

ByMULE MADHAV SHESHERAO

Under the Guidance of

GuideMr. Kshirsagar R. V.

Asst. ProfessorSchool of pharmacy SRTMU Nanded

Industrial GuideMr. N. K. ShindeSenior Executive

Lupin Research Park

School of Pharmacy, SRTMU, Nanded.

Page 2: Synopsis mule

2

The period between 1950 to 1970 is considered as period of

Sustained drug release.

The main AIM of preparing sustained release matrix tablet is

intended to modify and improve the drug performance by,

Increasing the duration of drug action and Absorption.

Avoid the fluctuation of plasma drug concentration.

Decreasing the frequency of dosing.

Decreasing the required dose employed.

Page 3: Synopsis mule

3

SR matrix tablet describes the slow release over extended

period of time.

The various type of matrices

1. Slow Eroding Matrix

2. Hydrophilic Matrix

3. Plastic Matrix

Page 4: Synopsis mule

4

Improved patient compliance: Less frequent dosing

Decreased local and systemic side effects. Decreased GIT irritation. Decreased local inflammation.

Better drug utilisation. Decreased total amount of drug used. Minimum drug accumulation on chronic dosing.

Improved efficiency in treatment. Uniform blood and plasma concentration. Decreased fluctuation in drug level Increased bioavailability of some drugs

Page 5: Synopsis mule

5

Dose Dumping: Increase quantity of drug release causes

dumping of drug which in turn leads to toxicity.

Reduced Potential For Accurate Dose Adjustment:

Administrating a fraction of drug is not possible.

Need For Additional Patient Education:

“Do not Crush or Chew the dosage unit”.

“ Tablet residue may appear in stools”.

Page 6: Synopsis mule

6

Antidepressant drug is used orally for the treatment of patients with

depression, caused by chemical imbalance on any other reasons. One

of the major problems of this drug is its very poor biological half life

(4hrs), which results in poor bioavailability after oral administration.

Antidepressant drug and its active metabolite inhibit the neuronal

uptake of norepinephrine, serotonin and to a lesser extent dopamine .

Hence it lacks the adverse anticholinergic, sedative and cardiovascular

effects of tricyclic antidepressants. It also requires low dose and it has

less dopamine reuptake activity as compared to other antidepressant

drug.

Page 7: Synopsis mule

7

1. To increase the Half life and bioavailability of antidepressant drug.

2. To provide a sustained release formulation of freely water soluble

drugs.

3. To provide a sustained release formulation capable of delivering the

drug substance within 24 hours.

4. To decrease side effect which shown by other antidepressant drug.

Page 8: Synopsis mule

8

1. Literature survey.

2. Selection of drug and Initial Studies of Marketed Product

Characterization and Selection of Excipients.

3. Drug excipients compatibility studies.

4. Preparation of trial formulation for in vitro evaluation.

5. Evaluation of trial formulation for every stage of manufacturing viz-

Mixing, blending, compression etc.

6. Evaluation of tablet

7. Stability studies of optimized formulation.

8. Scale-Up and Optimisation Trials towards Commercial Batches.

9. Interpretation of results and Thesis Submission.

Page 9: Synopsis mule

9

Margret Chandra et al, (2009): “formulation and evaluation of sustained release

matrix tablets of zidovudine”. By using Kollidon SR, Hydroxypropyl

methylcellulose K15M, K100M as matrix former.

Punit B. Parejiya et al, (2010): “Development and Characterization of Once a

Daily Tablet Formulation of Aceclofenac” Matrix tablets were prepared by direct

compression of Kollidon SR varying proportion with fixed percentage of

aceclofenac.

MD. Selim Reza et al, (2008): “Development of Theophylline Sustained Release

Dosage Form Based on Kollidon SR” Four matrix tablet formulations were

prepared by dry blending and direct compression of Kollidon SR and HPMC-

15cps.

Walid Sakr et al, (2009) Effect of Kollidon SR on the release of Albuterol

Sulphate from matrix tablets evaluate Kollidon SR for the development of extended

release Albuterol Sulphate matrix tablets.

Page 10: Synopsis mule

10

Drug Candidate: Antidepressant drug

Excipients

Silica colloidal anhydrous , Magnesium stearate, Calcium hydrogen phosphate

dehydrate, Kollidon SR, Macrogol 6000, Titanium Dioxide, Talcum, Ammonium methacrylate

copolymer dispersion(Eudragit RS 30D) Solvents: Distilled Water.

Preparation of sustained release matrix tablet by direct compression Method.

Page 11: Synopsis mule

11

Sr no Parameter Description

1 Category Antidepressant

2 Solubility 572mg\ml of water

3 Half life 5 hour

4 Mol. Wt. 313.87

5 pka 0.43

6 Dose 75 mg\day

7 Bioavailibility 45%

Page 12: Synopsis mule

12

1. Pre-compression Parameter . a) Bulk density b) Tapped density c) Compressibility Index and Hausner’s Ratio d) Angle of repose (θ)

2. Post- compression parameters. a) Weight variation b) Disintegration Test c) Friability d) Hardness and Thickness e) Dissolution Study f) Assay

Page 13: Synopsis mule

13

1. Simona JS, Aguiar LM. Extended Release Venlafaxine in Relapse Prevention for Patients with

Major Depressive Disorders, J Psychiatr Res. 38, 2004, 249-257.

2. Troy S.M, Parker VD, Fruncillo RJ, Chiang ST, the Pharmacokinetics of Venlafaxine When

Given in a Twicedaily Regimen. J Clin Pharmacol. 35, 1995, 404-409.

3. Gohel M.C,Bariya S.H.,“Fabrication of triple layer tablet of venlafaxine Hcl using xanthum

gum”AAPS PharmSciTech, june2009,10 (2);624-630.

4. Holliday SM, Benfield P. Venlafaxine: A review of its pharmacology and therapeutic potential

in depression drugs. Drugs. 1995;49:280–94.

5. Haskins JT, Moyer JA, Muth EA, Sigg EB. Inhibition of noradrenergic neuronal activity by

the novel bicyclic compounds, Wy-45,030 and Wy-45,881. Soc Neurosci Abstr. 1984;10:262.

6. Acute effectiveness of additional drugs to the standard treatment of depression. Available

from: http://ClinicalTrials.gov. [Last retrieved on 2005 June 23].  

7. Antidepressant discontinuation reactions. British Medical Journal (1998) 316: 1105-1106 (11

April).

8. Antidepressant drugs and generic counselling for treatment of major depression in primary

care: randomised trial with patient preference. British Medical Journal (2001) 322: 772 (31

March).

Page 14: Synopsis mule

14